ArticleCureus2025
Real-Time Adaptive Motion Management in Prostate Stereotactic Body Radiation Therapy: Clinical and Dosimetric Analysis of 25 Patients.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- MRI-guided adaptive stereotactic body radiotherapy for the prostate bed: a prospective study of safety, tolerability, and patient-reported quality-of-life outcomes.Clinical and translational radiation oncology · 2026Article
- Impact of Adaptive Radiation Therapy on Toxicity in Prostate Cancer: A Scoping Review.Biomedicines · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeStereotactic body radiation therapy (SBRT) is a well-established treatment for localized prostate cancer, offering excellent tumor control with reduced treatment fractions. However, prostate motion due to physiological processes poses a challenge to precise dose delivery. This study evaluates the dosimetric outcomes, prostate-specific antigen (PSA) response, and toxicity profile of prostate SBRT using real-time adaptive motion management with the Radixact Synchrony system (Accuray Inc., Madison, WI).
methodsA retrospective analysis was conducted on 25 prostate cancer patients treated with SBRT (40 Gy in 5 fractions) using the Radixact Synchrony system between January 2021 and December 2023. All patients underwent CT simulation with fiducial markers, and 24/25 patients had MRI fusion for target and organ-at-risk (OAR) delineation. Treatment plans were generated using either the "Classic" or "VOLO Ultra" algorithms. Intrafraction prostate motion was analyzed, and toxicity was assessed using the Common Terminology Criteria for Adverse Events (CTCAE) v4.03 scale at regular follow-up intervals.
resultsThe median clinical target volume (CTV) for the prostate was 46.8 cm³ (range, 22.6-107.3 cm³), and the median pre-treatment PSA was 6.52 ng/mL. All plans achieved favorable target coverage while adhering to OAR dose constraints. The median post-treatment PSA value was 0.30 ng/mL with a median follow-up time of 28 months, with all patients achieving PSA levels below 2.0 ng/mL at 15 months. Motion >2 mm was observed in at least one treatment fraction for all but one patient. Real-time adaptive motion management successfully corrected for prostate displacement, with an average imaging interval of 8.4 seconds. A total of 14 patients reported new grade 1 genitourinary (GU) symptoms, and three patients experienced grade 2 GU toxicity post-treatment.
conclusionProstate SBRT with real-time adaptive motion management using the Radixact Synchrony system achieves excellent target coverage while mitigating the effects of intrafraction motion. The observed PSA response supports its efficacy, and OAR dose metrics remain within acceptable limits. While real-time motion adaptation was beneficial for nearly all patients, further studies with larger cohorts and patient-reported outcomes are warranted to assess long-term toxicity and quality of life.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.